Glucagon-Like Peptide-1 Receptor Agonist and Basal Insulin Combination Treatment for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
The results, which were published in the Lancet on Thursday, are very encouraging for the safety and efficacy of orforglipron in people with type 2 diabetes, says Daniel Drucker, an endocrinologist at the University of Toronto, adding that he is awaiting further clinical trial results of the drug in people with obesity
Situations where CJC-1295 would generally be considered inappropriate or high-risk include: Active or prior cancer , given the theoretical role of elevated IGF-1 in tumor growth Diabetes or impaired glucose tolerance , because GH can worsen insulin resistance and raise blood sugar Pregnancy and breastfeeding , where there are no safety data whatsoever Children and adolescents , in whom manipulating the GH axis outside strict medical indications is inappropriate Serious cardiovascular, kidney, or liver disease , which fluid retention and metabolic shifts could aggravate Interactions to consider
Headquartered in Switzerland, the company is aiming to become one of the top five pharmaceutical companies in the United States by 2027 by taking a US-first mindset. In terms of drugs, Novartis heart drug Entresto (sacubitril/valsartan) had increased sales, resulting in 31 percent growth in sales in the past year to $4.64 billion
Shiba N, Shimokawa H
